"CONSISTENTLY REGARDED AS “THE LEADING LAWYER IN THE REGION" WHO’S WHO LEGAL 2015
Yuval Horn and Ohad Mamann of Horn & Co. represented Pontifax, who led a €16 million Series A round and restructuring in ABAC Therapeutics, Inc.
Yuval Horn, Paz Abercohen and Uri Dotan of Horn & Co. represented IOptima Ltd. and its shareholders, including Biolight Life Sciences Investments Ltd (TASE: BOLT) in a multi-stage acquisition transaction with an aggregate deal value of up to approximately $50 million, with Chengdu Kanghong Pharmaceutical Group, a Chinese life sciences company listed on the Shenzhen stock exchange.
Yuval Horn, Keren Kanir and Uri Dotan of Horn & Co. represented Vascular Biogenics Ltd. (Nasdaq: VBLT) in its $18.75 Million follow-on offering on NASDAQ.
Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences. Yuval Horn was noted as a Tier I practitioner. Legal 500 notes: “the firm has been active at the ‘top level’ in the healthcare sector for over 20 years”
Yuval Horn, Roy Ribon and Yasmin Zohar of Horn & Co. acted as Israeli counsel to Therapix Biosciences Ltd. (NASDAQ: TRPX) (TASE: THXBY), in its listing on Nasdaq and offering of $12 million
Horn & Co. once again recognized as one of the elite law firms in Israel by Dun & Bradstreet, in its 2017 ranking by fields of expertise